Groupe la Francaise Buys New Stake in Surmodics, Inc. $SRDX

Key Points

• Groupe la Francaise acquired 119,500 shares of Surmodics, Inc. for approximately $3.65 million, representing about 0.84% of the company, highlighting growing institutional interest in the stock.
• Surmodics recently reported earnings of $0.06 per share, beating the consensus estimate of ($0.21) by $0.27, with revenues of $29.57 million for the quarter.
• The stock currently has a consensus rating of "Hold," with a target price of $43.00, indicating cautious sentiment among analysts regarding its future performance.

Groupe la Francaise purchased a new position in Surmodics, Inc. (NASDAQ:SRDX - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 119,500 shares of the company's stock, valued at approximately $3,648,000. Groupe la Francaise owned approximately 0.84% of Surmodics at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of SRDX. Deutsche Bank AG lifted its holdings in shares of Surmodics by 77.8% during the fourth quarter. Deutsche Bank AG now owns 42,683 shares of the company's stock valued at $1,690,000 after purchasing an additional 18,671 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Surmodics by 40.9% in the 4th quarter. Wells Fargo & Company MN now owns 7,032 shares of the company's stock worth $278,000 after buying an additional 2,041 shares during the last quarter. Bardin Hill Management Partners LP purchased a new position in shares of Surmodics in the 4th quarter worth $7,440,000. Hudson Bay Capital Management LP purchased a new stake in Surmodics during the fourth quarter valued at $11,880,000. Finally, Marshall Wace LLP increased its position in Surmodics by 231.0% during the fourth quarter. Marshall Wace LLP now owns 28,135 shares of the company's stock valued at $1,114,000 after acquiring an additional 19,635 shares during the last quarter. 96.63% of the stock is owned by institutional investors.

Surmodics Stock Performance

Shares of Surmodics stock traded down $0.09 on Friday, hitting $34.24. 12,096 shares of the company's stock were exchanged, compared to its average volume of 193,033. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.10 and a current ratio of 3.91. Surmodics, Inc. has a 1 year low of $26.00 and a 1 year high of $40.38. The company has a 50-day simple moving average of $33.29 and a 200-day simple moving average of $30.98. The stock has a market capitalization of $489.55 million, a PE ratio of -27.83 and a beta of 1.31.

Surmodics (NASDAQ:SRDX - Get Free Report) last released its earnings results on Friday, August 8th. The company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.27. Surmodics had a negative net margin of 14.59% and a negative return on equity of 2.99%. The company had revenue of $29.57 million for the quarter, compared to analysts' expectations of $28.04 million. Surmodics has set its FY 2025 guidance at -0.350--0.200 EPS. As a group, equities analysts anticipate that Surmodics, Inc. will post 0.2 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Barrington Research reiterated a "market perform" rating on shares of Surmodics in a research report on Monday, August 11th. Zacks Research upgraded Surmodics to a "hold" rating in a research report on Tuesday, August 12th. One investment analyst has rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $43.00.

Surmodics Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).